Showing results (971-980 of 6,392) with videos related to

Sort By:
Pageof 640
World Journal of Urology|October 14, 2022
Transurethral resection of the prostate in 85+ patients: a retrospective, multicentre studyMichael Lotterstätter, Stephan Seklehner, Florian Wimpissinger, et al.
World Journal of Urology|September 2, 2022
Predictors of ultrasound abnormalities among women treated for community-onset acute pyelonephritis: a prospective studyFranck Bruyère, Yoann Conan, Maxime Vallée, et al.
World Journal of Urology|September 6, 2022
Fluoroscopy screening time and radiation dose during complete supine percutaneous nephrolithotomySiavash Falahatkar, Purya Haghjoo, Samaneh Esmaeili, et al.
World Journal of Urology|September 15, 2022
A systematic review of treatment options for post-prostatectomy incontinenceAlexander Canning, Nicholas Raison, Abdullatif Aydin, et al.
World Journal of Urology|September 15, 2022
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancerAlbert Font, Montserrat Domenech, Oscar Buisan, et al.
World Journal of Urology|November 1, 2022
Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequencesMaximilian Haack, Vanessa Miksch, Zhe Tian, et al.
World Journal of Urology|October 28, 2022
Ultrasound-guided percutaneous nephrolithotomy in patients with retrorenal colon: a single-center experienceAmir Hossein Kashi, Akbar Nouralizadeh, Mehdi Sotoudeh, et al.
World Journal of Urology|September 20, 2022
Does the 5-item Frailty Index predict surgical complications of endoscopic surgical management for benign prostatic obstruction? An analysis of the ACS-NSQIPMuhieddine Labban, Nicola Frego, Zhiyu Qian, et al.
World Journal of Urology|September 20, 2022
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?Giuseppe Fallara, Alessandro Larcher, Giuseppe Rosiello, et al.
World Journal of Urology|October 2, 2022
Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectivesIgor Tsaur, Roman A Blaheta, Robert Dotzauer, et al.
Pageof 640